Highlights and Quick Summary
- Non-operating Income/Expense for the quarter ending March 31, 2022 was $-256 Thousand (a 6300.0% increase compared to previous quarter)
- Year-over-year quarterly Non-operating Income/Expense increased by 700.0%
- Annual Non-operating Income/Expense for 2021 was $-38 Thousand (a -89.11% decrease from previous year)
- Annual Non-operating Income/Expense for 2020 was $-349 Thousand (a -166.99% decrease from previous year)
- Annual Non-operating Income/Expense for 2019 was $521 Thousand (a -13.74% decrease from previous year)
- Twelve month Non-operating Income/Expense ending March 31, 2022 was $-303 Thousand (a 697.37% increase compared to previous quarter)
- Twelve month trailing Non-operating Income/Expense increased by 95.48% year-over-year
Trailing Non-operating Income/Expense for the last four month:
| 31 Mar '22 | 31 Dec '21 | 30 Sep '21 | 30 Jun '21 |
|---|---|---|---|
| $-303 Thousand | $-38 Thousand | $-58 Thousand | $-155 Thousand |
Visit stockrow.com/ALNA
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Non-operating Income/Expense of Allena Pharmaceuticals, Inc.
Most recent Non-operating Income/Expenseof ALNA including historical data for past 10 years.Interactive Chart of Non-operating Income/Expense of Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. Non-operating Income/Expense for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | $-0.26 | – | – | – | – |
| 2021 | $-0.0 | $-0.01 | $-0.03 | $0.01 | $-0.04 |
| 2020 | $-0.02 | $-0.11 | $-0.42 | $-0.06 | $-0.35 |
| 2019 | $-0.07 | $0.05 | $0.06 | $0.14 | $0.52 |
| 2018 | $0.17 | $0.2 | $-0.51 | $0.09 | $0.6 |
| 2017 | $-0.11 | $-0.31 | $-0.16 | $-0.13 | $-0.26 |
| 2016 | – | – | – | $-0.03 | $-0.32 |
| 2015 | – | – | – | – | $-0.34 |
Business Profile of Allena Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.